Press release
Principles and Applications of Bio-Layer Interferometry (BLI)
IntroductionANTIBODY
Modern analytical labs use Bio-Layer Interferometry. It is a label-free technology. Researchers measure the affinity and kinetics of biomolecules in real-time. kon and koff values are more useful than a single ELISA endpoint. A fiber-optic biosensor tip is used to detect interference patterns. White light reflects from two surfaces. One is the protein layer and the other is a reference. Thickness increase when molecules bind to the tip. This shift the wavelength by 0.1 nm to 10 nm. The instrument records these changes.The industry refers to this method as BLI. It can handle crude samples like cell lysates. Culture supernatants are used without clogging any fluidic channels. This robustness is important when sample purity is below 50%. Small molecules and large 150 kDa proteins are both tested. The workflow is consistent across different research needs.
Core Experimental Workflow and Setup
ANTIBODY
The typical workflow for Bio-Layer Interferometry has several steps. Success at the bench depends on sensor and plate preparation. Most protocols follow a specific method.
Image: https://ecdn6.globalso.com/upload/p/1443/image_other/2026-04/fig-1-steps-and-analysis-of-bli-experiments.jpg
1. Sensor Pre-hydration
Sensors are soaked in 200 L of buffer, which must match the experimental conditions. The process takes at least 10 minutes and plays a critical role in stabilizing the optical layer. Proper pre-hydration helps prevent signal drifting during the initial baseline stage.
2. Initial Baseline
Sensors are dipped into a buffer to establish a steady starting signal. This step typically lasts between 60 to 120 seconds, with data recorded at 5.0 Hz or 10.0 Hz.
3. Loading
During this step, the ligand is immobilized on the sensor surface. For Streptavidin (SA) sensors, biotinylated proteins or aptamers are commonly used. Typical concentrations range from 5 to 20 g/mL, achieving a target shift of 0.5 nm to 2.0 nm.
4. Second Baseline
A brief wash step is performed to remove unbound ligand. This ensures that the loaded surface is stable before interaction begins. The second baseline usually runs for about 60 seconds.
5. Association
The loaded sensors are transferred into wells containing the analyte. This is where binding occurs, and data for the association rate constant (kon) is collected.
6. Dissociation
Sensors are moved back into buffer wells. The rate at which the analyte dissociates from the ligand is measured to determine the dissociation rate constant (koff).
7. Shaking Speed Considerations
Shaking speed is a critical parameter throughout the experiment. Most researchers set the orbital shaker to 1000 RPM to minimize mass transport effects. If the shaking speed is too low, molecular movement to the sensor surface becomes limiting, leading to inaccurate kinetic calculations.
8. Applications in Aptamer Screening
Bio-Layer Interferometry enables faster aptamer screening through label-free detection. Aptamers are synthetic oligonucleotide sequences that fold into three-dimensional structures to bind specific targets. The goal is to achieve KD values in the low nanomolar range with high specificity.
Immobilization is typically straightforward, with biotin tags added to sequences for high-density loading on SA sensors. Aptamer folding is an important factor: samples are heated to 95 degrees C for 5 minutes and then slowly cooled to 25 degrees C. Magnesium ions (Mg) at concentrations of 1-5 mM are added to the buffer to activate the molecules.
Competition assays can also be performed. One aptamer is pre-bound to the target, followed by introduction of a second sequence to determine whether they share the same epitope. Stability throughout the ~30-minute experiment is essential, making buffer selection critical.
9. Peptide Screening and Integration with Phage Display
This technology is widely used in peptide screening for drug development. Peptides are typically smaller than 5 kDa, often resulting in low signal-to-noise ratios. To compensate, larger proteins are immobilized on the sensor, while peptides are used as analytes at concentrations of 50 M to 100 M.
Phage display is commonly used to generate large libraries of potential binders. After multiple rounds of panning, clones must be validated. Bio-Layer Interferometry allows rapid secondary screening by ranking candidates based on off-rates.
Typical workflow includes:
* Target proteins are expressed with His-tag or GST-tag.
* Targets are captured on Ni-NTA or Anti-GST sensors.
* The enriched pool is tested against the target.
* Individual clones are selected for detailed screening.
Non-specific binding (NSB) is a common issue. To reduce background noise, 0.02% Tween-20 or 0.1% BSA is added to the buffer. This ensures that binding curves reflect true interactions rather than random stickiness.
10. Practical Considerations for Bench-Level Work
When setting up a BLI experiment, several practical factors are essential:
* Temperature control: Typically set at 25 degrees C or 37 degrees C. Even a 1 degrees C fluctuation can affect buffer viscosity and binding kinetics, leading to inconsistent results.
* Reference subtraction: Include controls such as empty sensors or irrelevant proteins dipped into analyte, as well as loaded sensors dipped into buffer. Subtracting these signals helps correct background drift and non-specific binding.
* Sensor selection: Depends on the application. Protein A or G sensors are suitable for antibody capture, while SA sensors are preferred for aptamers.
* Regeneration: Sensors can often be reused by applying three short pulses (5 seconds each) of low pH buffer, such as 10 mM glycine (pH 1.5-2.0), to remove bound molecules.
11. Conclusion
Bio-Layer Interferometry provides a robust platform for molecular interaction studies, delivering kinetic data without the need for fluorescent labels. It is widely used in aptamer screening and phage display validation, supporting lead optimization in drug development.
Successful experiments depend on careful parameter optimization. Standard conditions include shaking speeds around 1000 RPM, proper buffer composition, and strict temperature control. Addressing non-specific binding is also critical for accurate results.
As an alternative to complex fluidic systems, BLI offers high throughput and efficiency, making it a valuable tool in modern biopharmaceutical research.
Media Contact
Company Name: Alpha Lifetech Incorporation
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=principles-and-applications-of-biolayer-interferometry-bli]
Phone: +1 609-736-0910
Address:90 State Street, STE 700 Office 40
City: Albany
State: NY 12207
Country: China
Website: https://www.alpha-lifetech.com/
Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Principles and Applications of Bio-Layer Interferometry (BLI) here
News-ID: 4482584 • Views: …
More Releases from ABNewswire
Myasthenia Gravis Clinical Trial Pipeline Shows Potential with Active Contributi …
DelveInsight's, "Myasthenia Gravis Pipeline Insight 2026" report provides comprehensive insights about 25+ companies and 30+ pipeline drugs in Myasthenia Gravis pipeline landscape. It covers the Myasthenia Gravis Pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Myasthenia Gravis Pipeline Therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Curious about the latest updates in…
Non-Alcoholic Steatohepatitis Pipeline Set for Transformational Expansion by 202 …
Key Non-Alcoholic Steatohepatitis (NASH) Companies include Novo Nordisk, Viking Therapeutics, Inventiva Pharma, GlaxoSmithKline, Haisco Pharmaceutical Group, and others
The Non-Alcoholic Steatohepatitis (NASH) therapeutic landscape is entering a pivotal phase of innovation and clinical acceleration, driven by an expanding pipeline and increasing scientific understanding of disease biology. Companies such as Novo Nordisk, Viking Therapeutics, Inventiva Pharma, GlaxoSmithKline, and Haisco Pharmaceutical Group are at the forefront of reshaping the future of NASH treatment…
STAT Inhibitors Pipeline Set for Breakthrough Innovation by 2026 with 22+ Therap …
Key STAT Inhibitors Companies include Tvardi Therapeutics, Kymera Therapeutics, Recludix Pharma, Enanta Pharmaceuticals, Moleculin, Purple Biotech, LEO Pharma, JW Pharmaceutical, KAKEN PHARMACEUTICAL, C4XD Holdings, and others
The STAT inhibitors therapeutic landscape is undergoing a significant transformation, driven by rapid scientific advancements and increasing clinical activity across oncology and immunology indications. Companies such as Tvardi Therapeutics, Kymera Therapeutics, Inc., Recludix Pharma, Enanta Pharmaceuticals, Moleculin, Inc., Purple Biotech, LEO Pharma A/S, JW Pharmaceutical,…
Diabetic Neuropathy Pipeline Set for Significant Breakthroughs by 2026 with 20+ …
Leading diabetic neuropathy companies include Vertex Pharmaceuticals Incorporated, Novaremed, Trevena, Inc., WinSanTor, Inc., AlgoTherapeutix, Tris Pharma, Inc., JMackem Co., Ltd, Lexicon Pharmaceuticals, Merz Pharmaceuticals GmbH, and others are evaluating new diabetic neuropathy drugs to improve the treatment landscape.
The Diabetic Neuropathy therapeutic landscape is undergoing a transformative shift, driven by increasing research investments and a strong pipeline of innovative therapies. Companies such as Vertex Pharmaceuticals Incorporated, Lexicon Pharmaceuticals, Trevena, Novo Nordisk…
More Releases for Interferometry
Bio-Layer Interferometry (BLI) Instruments Research:CAGR of 7.7% during the fore …
QY Research Inc. (Global Market Report Research Publisher) announces the release of 2025 latest report "Bio-Layer Interferometry (BLI) Instruments- Global Market Share and Ranking, Overall Sales and Demand Forecast 2025-2031". Based on current situation and impact historical analysis (2020-2024) and forecast calculations (2025-2031), this report provides a comprehensive analysis of the global Wire Drawing Dies market, including market size, share, demand, industry development status, and forecasts for the next few…
Bio-Layer Interferometry (BLI) Service Market Revenue, Insights, Overview, Outlo …
Bio-Layer Interferometry (BLI) Service Market
The global Bio-Layer Interferometry (BLI) Service market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of %during the forecast period 2024-2030.
Get Free Sample: https://reports.valuates.com/request/sample/QYRE-Auto-23Q17152/Global_Bio_Layer_Interferometry_BLI_Service_Market_Research_Report_2024
Major Factors:
Global Bio Layer Interferometry (BLI) service is revolutionizing the biophysical analysis landscape by providing real-time, label‐free detection of molecular interactions. Increasing demand for rapid drug discovery and precise biomolecular characterization is…
Interferometry Market by Types, Applications, Manufacturers, End User - Global F …
Interferometers work by merging two or more sources of light to create an interference pattern, which can be measured and analyzed; hence "Interfere-ometer".
Interferometry report published by QYResearch reveals that COVID-19 and Russia-Ukraine War impacted the market dually in 2022. Global Interferometry market is projected to reach US$ 846.7 million in 2029, increasing from US$ 619.9 million in 2022, with the CAGR of 4.5% during the period of 2023 to 2029.…
Global White Light Interferometry (WLI) Market to Witness a Pronounce Growth Dur …
Market Research Report Store offers a latest published report on White Light Interferometry (WLI) Market Analysis and Forecast 2019-2025 delivering key insights and providing a competitive advantage to clients through a detailed report.
The White Light Interferometry (WLI) market was valued at xx Million US$ in 2018 and is projected to reach xx Million US$ by 2025, at a CAGR of xx% during the forecast period. In this study, 2018 has…
White Light Interferometry Market Size, Share, Development by 2024
Global Info Research offers a latest published report on White Light Interferometry Market Analysis and Forecast 2019-2025 delivering key insights and providing a competitive advantage to clients through a detailed report. This report focuses on the key global White Light Interferometry players, to define, describe and analyze the value, market share, market competition landscape, SWOT analysis and development plans in next few years.
To analyze the White Light Interferometry with respect…
Interferometry Market Size, Share, Development by 2024
Global Info Research offers a latest published report on Interferometry Market Analysis and Forecast 2019-2025 delivering key insights and providing a competitive advantage to clients through a detailed report. This report focuses on the key global Interferometry players, to define, describe and analyze the value, market share, market competition landscape, SWOT analysis and development plans in next few years.
To analyze the Interferometry with respect to individual growth trends, future prospects,…
